PLx Pharma (NASDAQ:PLXP) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Monday.

Separately, Zacks Investment Research cut shares of PLx Pharma from a “buy” rating to a “hold” rating in a report on Saturday, August 19th.

PLx Pharma (PLXP) opened at $6.65 on Monday. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56. PLx Pharma has a twelve month low of $5.60 and a twelve month high of $22.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of PLx Pharma during the third quarter valued at approximately $145,000. University of Texas Investment Managment Co. bought a new stake in PLx Pharma during the second quarter valued at approximately $385,000. Finally, Susquehanna International Group LLP bought a new stake in PLx Pharma during the second quarter valued at approximately $1,413,000. 21.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.